Isolated limb perfusion
Abstract
Isolated limb perfusion is a surgical procedure that can be used to treat an advanced malignant melanoma and soft tissue sarcomas, it is also effective in treating in-transit metastases of melanoma and local metastases of soft tissue sarcomas. With perfusion of the affected limb with cytostatic agents it is possible to avoid amputation and mutilating operations that significantly reduced the function of the limb. Since the procedure is isolated on a limb, it can be perfused with much higher doses of cytotoxic drugs, systemic toxicity is thus reduced or prevented. The most common side effects are erythema and edema.
Cytotoxic drugs, that are manly used, are melphalan and tumor necrosis factor alpha. Efficient also proved to be simultaneous hyperthermia of the affected limb.
Downloads
References
Creech O, Krementz ET, Ryan RF et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–31
Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet. 1969;129:305–8.
Klauser MJ, Lev-Chelouche D, Meller I. et al. Musculoskeletal Cancer Surgery Musculoskeletal Cancer Surgery Treatment of Sarcomas and Allied Diseases. Ch. 04 Isolated-limb perfusion in the treatment of advanced soft-tissue sarcomas. 2001 [citirano 2015 Jan 3]. Dosegljivo na: http://www.sarcoma.org/publications/mcs/ch4.pdf
Bračko M. Patologija malignega melanoma. Radiol Oncol 2007 (Suppl 1): S13-s17 [citirano 2015 Jan 23]. Dosegljivo na: http://www.onko-i.si/fileadmin/onko/datoteke/dokumenti/Radiology_41_Supp1_3.pdf
Nieweg E.O., Kroon B.R.B.. Isolated Limb Perfusion with Melphalan for Melanoma. J. Surg. Oncol. 2014
Bračko M., Novak J. Sarkomi mehkih tkiv. Onkologija pregledi. [citirano 2015 Jan 24]. Dosegljivo na: http://www.onko-i.si/fileadmin/onko/datoteke/dokumenti/2-2001-bracko.pdf
Kim J.C., Puleo C., Letson D.G. et al. Hyperthermic Isolated Limb Perfusion for Extremity Sarcomas. Cancer Control. May/June 2001, Vol. 8, No. 3
Eggermont M.M.A., Koops Schraffordt H., Klausner M.J. Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Sarcomas. Annals of Surgery. Vol. 224, No. 6, 756-765. 1996.
Di Filippo F., Giacomini P., Rosso C. R. et al. Prognostic Factors Influencing Tumor Response, Locoregional Control and Survival, in Melanoma Patients with Multiple Limb In-transit Metastases Treated with TNFα-based Isolated Limb Perfusion. In vivo 23. 347-352. 2009.
Deroose P. J., Eggermont M. M. A., van Geel. N. A. et al. 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases. Annals of Surgical Oncology 19. 627-635. 2012
Vrouenrates C. B., Klaase M. J., Nieweg E. O. et al. Toxicity and Morbidity of Isolated Limb Perfusion. Seminar in Surgical Oncology 14. 224-231. 1998.
Kroon M. H. Treatment of Locally Advanced Melanoma by Isolated Limb Infusion with Cytotoxic Drugs. Journal of Skin Cancer Vol. 2011. Article ID 106573
Sharma K., Beasley G., Turley R. et al. Petterns of Recurrence Followinh Complete Response to Regional Chemotherapy for In-Transit Melanoma. Ann Surg Oncol 2012 19: 2563-2571
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
